Boehringer Ingelheim Corporate News This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Initial results from EMPRISE real-world evidence study shows empagliflozin was associated with reduced risk for hospitalisation for heart failure compared with DPP-4 inhibitors in people with type 2 diabetes with and without cardiovascular disease
Empagliflozin was associated with a 44 percent reduction in relative risk of hospitalization for heart failure (HHF) compared with commonly used dipeptidyl peptidase-4 inhibitors1Effect of empagliflozin on HHF was consistent in patients with and without established cardiovascular disease1Findings support data from the landmark EMPA-REG OUTCOME ® trial, in which empagliflozin reduced the relative risk of HHF by 35 percent in people with type 2 diabetes and established cardiovascular disease2 (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 5, 2018 Category: Research Source Type: news

Extension_BioXcellence_Fremont
Boehringer Ingelheim achieves next expansion milestone in biologics production in the USCulmination of a €200 million investment in CaliforniaWorldwide capacity for manufacturing biopharmaceutical medicines now exceeds 290,000 litersGlobal manufacturing network for products in Boehringer Ingelheim ’s own research pipeline and for contract manufacturing (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - October 30, 2018 Category: Research Source Type: news

New working environment for agile working methods
Boehringer Ingelheim inaugurates new centre for agile working methods: more and better health solutions for humans and animalsNew building inaugurated exclusively for agile working methods in IngelheimAgile Facilitators strengthen Boehringer Ingelheim from ideation to development of scalable solutions for human and animal health  (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - October 25, 2018 Category: Research Source Type: news

Winners of 2018 BVDzero Case Awards
Boehringer Ingelheim announces the winners of 2018 BVDzero Case AwardsBoehringer Ingelheim grants a total prize of 15,000  euros to the top 10 clinical casesBoehringer Ingelheim encourages the search for both clinical and subclinical cases of bovine viral diarrhea (BVD) in cattle herds, aiming to improve BVD awareness (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - October 19, 2018 Category: Research Source Type: news

GioTag_sequencing_results
Real-world study shows using Giotrif ®/Gilotrif® (afatinib) followed by osimertinib provides a median of 27.6 months of chemotherapy-free time in patients with EGFR mutation-positive NSCLCGioTag is the first global, real-world study to evaluate the sequencing of targeted treatments in patients with the most common acquired treatment resistance mutation1  Results published today in Future Oncology1   (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - October 18, 2018 Category: Research Source Type: news

Results from two Pradaxa trials to be presented at WSC
Results from Pradaxa ® RE-SPECT ESUS® and RE-SPECT CVT® trials to be presented at the 11th World Stroke CongressData from key trials will aid in increasing scientific understanding of ESUS and CVTRESPECT-ESUS is first randomised trial to investigate clinical profile of Pradaxa ® vs ASA (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - October 12, 2018 Category: Research Source Type: news

health project elephants
Boehringer Ingelheim increases awareness of health with the micro enterprise project ‘Elephants’ in South IndiaBoehringer Ingelheim launches new health project in Coimbatore/IndiaProject to raise awareness about infections with communicable diseases due to bad hygiene and the importance of handwashing with soap  Trainings will enable participants to start own soap manufacturing business (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - October 12, 2018 Category: Research Source Type: news

Inauguration of new global center for veterinary vaccine R & D
Boehringer Ingelheim inaugurates its new global centre for veterinary vaccine R&D in Lyon, France70 million euro investment reinforces the company ’s leading position in the veterinary vaccine marketThe new R&D center of 14,500 square meters is a high-tech facility employing more than 200 employees (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - October 10, 2018 Category: Research Source Type: news

2018 Animal Welfare Medals
: Boehringer Ingelheim recognizes outstanding research in animal healthBoehringer Ingelheim honors research papers on innovative health solutions for improving animal welfareIndependent jury awards prizes in the folowing categories: cattle, equine, swine, as well as small animals and petsThe  awards demonstrate focus on prevention, animal well-being and innovative solutions (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - October 10, 2018 Category: Research Source Type: news

Empa T1D Full Data
Boehringer Ingelheim and Lilly present full results from EASE Phase III programme for empagliflozin as adjunct to insulin in type 1 diabetesAll investigated doses met the primary efficacy endpoint defined as a change from baseline in HbA1c versus placebo after 26 weeks of treatment  Regulatory discussions initiated for empagliflozin, as adjunct to insulin, in type 1 diabetes  Full results presented at the 54th European Association for the Study of Diabetes Annual Congress (EASD) and published online in Diabetes Care ahead of print1 (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - October 4, 2018 Category: Research Source Type: news

Boehringer Ingelheim is committed to joining forces in the global fight against rabies
The company ’s goal is to bring attention to the serious threat that rabies still poses to animals and humans in many parts of the worldAn estimated 160 people die from rabies every day, 40 per cent of whom are children1Human rabies deaths could be avoided through effective dog vaccination1 (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - September 28, 2018 Category: Research Source Type: news

New vaccine against Bovine Respiratory Disease
: Boehringer Ingelheim reaffirms its focus on preventionBovalto ® Respi Intranasal now registered in most European countries for active immunization of cattle against Bovine Respiratory Syncytial Virus (BRSV) and Bovine Parainfluenza 3 Virus (PI3V), two of the major pathogens involved in Bovine Respiratory Disease (BRD)BRD is one of the most common diseases1 affecting cattle all over the worldBoehringer Ingelheim reaffirms its focus on prevention and animal well-being (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - September 27, 2018 Category: Research Source Type: news

NSCLC_treatment_sequencing_survey
Global survey reveals that physicians need more information to assess the impact of treatment sequencing on patient survival in EGFR mutation-positive NSCLC  More than one-third of physicians report not having sufficient information to decide on how to sequence specific targeted lung cancer treatmentsSurvey findings presented today as a late-breaking abstract at the 2018 World Conference on Lung Cancer (WCLC) in Toronto, Canada   (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - September 26, 2018 Category: Research Source Type: news

Lume Meso Phase III Results
Results of LUME-Meso trial in malignant pleural mesothelioma presented at the 19th World Conference on Lung Cancer (WCLC 2018)The primary endpoint of progression-free survival was not met in the Phase III LUME-Meso Trial (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - September 25, 2018 Category: Research Source Type: news

Empa long-term survival benefit
New analysis estimates the positive impact of empagliflozin on prolonging life expectancy in adults with type 2 diabetes and established cardiovascular diseaseSurvival estimates from the EMPA-REG OUTCOME ® trial data demonstrate potential long-term benefit of empagliflozin (marketed as Jardiance®) on life expectancy of adults with type 2 diabetes and cardiovascular disease1 (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - September 25, 2018 Category: Research Source Type: news